English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
 
 
DownloadE-Mail
  Ether à go-go potassium channel expression in soft tissue sarcoma patients

Mello de Queiroz, F., Suarez-Kurtz, G., Stühmer, W., & Pardo, L. A. (2006). Ether à go-go potassium channel expression in soft tissue sarcoma patients. Molecular Cancer, 5: 42. doi:10.1186/1476-4598-5-42.

Item is

Files

show Files
hide Files
:
Mello_06.pdf (Any fulltext), 2MB
Name:
Mello_06.pdf
Description:
-
OA-Status:
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
eDoc_access: PUBLIC
License:
-

Locators

show

Creators

show
hide
 Creators:
Mello de Queiroz, Fernanda1, Author           
Suarez-Kurtz, Guilherme, Author
Stühmer, Walter1, Author           
Pardo, Luis A.1, Author           
Affiliations:
1Molecular biology of neuronal signals, Max Planck Institute of Experimental Medicine, Max Planck Society, ou_2173656              

Content

show
hide
Free keywords: EAG K+ CHANNELS; MELANOMA-CELLS; PROLIFERATION; IMIPRAMINE
 Abstract: Background: The expression of the human Eag1 potassium channel (Kv10.1) is normally restricted to the adult brain, but it has been detected in both tumour cell lines and primary tumours. Our purpose was to determine the frequency of expression of Eag1 in soft tissue sarcoma and its potential clinical implications. Results: We used specific monoclonal antibodies to determine the expression levels of Eag1 in soft tissue sarcomas from 210 patients by immunohistochemistry. Eag1 was expressed in 71% of all tumours, with frequencies ranging from 56% (liposarcoma) to 82% (rhabdomyosarcoma). We detected differences in expression levels depending on the histological type, but no association was seen between expression of this protein and sex, age, grade or tumour size. Four cell lines derived from relevant sarcoma histological types (fibrosarcoma and rhabdomyosarcoma) were tested for Eag1 expression by real-time RT-PCR. We found all four lines to be positive for Eag1. In these cell lines, blockage of Eag1 by RNA interference led to a decrease in proliferation. Conclusion: Eag1 is aberrantly expressed in over 70% sarcomas. In sarcoma cell lines, inhibition of Eag1 expression and/or function leads to reduced proliferation. The high frequency of expression of Eag1 in primary tumours and the restriction of normal expression of the channel to the brain, suggests the application of this protein for diagnostic or therapeutic purposes.

Details

show
hide
Language(s): eng - English
 Dates: 2006-10
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: Peer
 Identifiers: eDoc: 292149
ISI: 000241387400001
ISI: 000241387400001
DOI: 10.1186/1476-4598-5-42
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Molecular Cancer
  Alternative Title : Mol. Cancer
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 5 Sequence Number: 42 Start / End Page: - Identifier: ISSN: 1476-4598